Connect Biopharma Holdings Limited
CNTB · NASDAQ
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.00 | -0.02 | 0.08 |
| FCF Yield | -23.71% | -20.86% | -10.59% | -25.93% |
| EV / EBITDA | -1.10 | 0.08 | -3.71 | 1.43 |
| Quality | ||||
| ROIC | -18.47% | -26.74% | 6.52% | -26.72% |
| Gross Margin | 100.00% | 90.40% | 98.03% | 0.00% |
| Cash Conversion Ratio | 0.98 | 0.67 | -1.30 | 0.53 |
| Growth | ||||
| Revenue 3-Year CAGR | 2,965,282.90% | 2,963,462.26% | 2,889,038.92% | -100.00% |
| Free Cash Flow Growth | 18.85% | -88.94% | 50.09% | 46.29% |
| Safety | ||||
| Net Debt / EBITDA | 3.00 | 3.41 | -13.40 | 3.72 |
| Interest Coverage | 0.00 | 0.00 | 365.40 | 2,621.31 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 361.88 | -118.24 | 14.36 | -1,430.67 |